Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

SIX1 Is a Novel Effector Gene in CALM-AF10 Leukemia

Waitman K. Aumann, MDMS, Catherine P. Lavau, DVM, PhD, Amanda Harrington, MD, Amanda E. Conway, PhD, Daniel S. Wechsler, MD PhD

Blood (2019) 134 (Supplement_1): 5035.

https://doi.org/10.1182/blood-2019-130178

Published: 2019

Journal Articles

A Role for the CRM1 Nuclear Export Receptor in HOXA Gene Deregulation and CALM-AF10 Leukemogenesis

Waitman K. Aumann, MD, Jessica L. Heath, MD, Sei-Gyung K. Sze, MD, Amanda E. Conway, PhD, Catherine P. Lavau, DVM, PhD, Daniel S. Wechsler, MD PhD

Blood (2017) 130 (Supplement 1): 369.

https://doi.org/10.1182/blood.V130.Suppl_1.369.369

Published: 2017

Journal Articles

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Marsha L. Crochiere, PhD, Stefan Hannus, PhD, Kerrin Hansen, Frank Becker, PhD, Erkan Baloglu, PhD, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 1563.

https://doi.org/10.1182/blood.V128.22.1563.1563

Published: 2016

Journal Articles

Development of a Pharmacodynamic Assay for XPO1 Occupancy Using Fluorescence Cross Correlation Spectroscopy (FCCS)

Marsha L. Crochiere, PhD, Stefan Hannus, PhD, Kerrin Hansen, Frank Becker, PhD, Joel Ellis, PhD, Margaret S. Lee, PhD, Yosef Landesman, PhD

Blood (2015) 126 (23): 2487.

https://doi.org/10.1182/blood.V126.23.2487.2487

Published: 2015

Journal Articles

XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia

Flavia Guillem, PhD, Michael Dussiot, PhD, Sebastien Causse, PhD, Guillaume Marcion, Emilie-Fleur Gautier, PhD, Julien Rossignol, MD, Jean benoit Arlet, MD PhD, Mathilde Lamarque, MD, Patrick Mayeux, PhD, Frederique Verdier, PhD, Xiuli An, MD PhD, Jean-Antoine Ribeil, MD PhD, Carmen Garrido, PhD, Genevieve Courtois, PhD, Narla Mohandas, D.Sc., Olivier Hermine

Blood (2015) 126 (23): 2368.

https://doi.org/10.1182/blood.V126.23.2368.2368

Published: 2015

Journal Articles

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Janice Chen, PhD, Christopher L. Brooks, PhD, Peter McDonald, Jonathan D. Schwartz, MD, Rebecca S. Schneider, Keiichi Sakakibara, PhD, Naoya Saito, PhD, Takuji Sato, MSc, Takumi Kawabe, MD PhD, Eric K. Rowinsky, MD

Blood (2015) 126 (23): 4433.

https://doi.org/10.1182/blood.V126.23.4433.4433

Published: 2015

Journal Articles

ANKHD1 Is Required for S Phase Progression and Histone Gene Transcription in Multiple Myeloma

Anamika Dhyani, PhD, Patricia Favro, Sara T O Saad, MD PhD

Blood (2014) 124 (21): 2002.

https://doi.org/10.1182/blood.V124.21.2002.2002

Published: 2014

Journal Articles

The CRM1 Nuclear Export Receptor Activates HOXA Gene Expression in Leukemogenesis

Catherine P Lavau, DVM, PhD, Jessica L Heath, MD, William H Lee, Amanda E Conway, PhD, Daniel S Wechsler, MD PhD

Blood (2014) 124 (21): 2190.

https://doi.org/10.1182/blood.V124.21.2190.2190

Published: 2014

Journal Articles

Cytoplasmic-Nuclear Shuttling of mTOR Protein in Multiple Myeloma Cell Lines and Primary Myeloma Cells: A New Mechanism Regulated by Pomalidomide

Tommasina Guglielmelli, MD, Emilia Giugliano, PhD, Vanessa Brunetto, PhD, Sokol Rrodhe, MD, Giuseppe Saglio, MD

Blood (2012) 120 (21): 4019.

https://doi.org/10.1182/blood.V120.21.4019.4019

Published: 2012

Journal Articles

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

Keiichi Sakakibara, Naoya Saito, Takuji Sato, Atsushi Suzuki, Yoko Hasegawa, Jonathan M. Friedman, Donald W. Kufe, Daniel D. VonHoff, Tadahiko Iwami, Takumi Kawabe

Blood (2011) 118 (14): 3922–3931.

https://doi.org/10.1182/blood-2011-01-333138

Published: 2011

Includes: Supplemental data

Journal Articles

BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells.

Michele Massimino, PhD, Livia Manzella, MD, PhD, Fabio Stagno, Maria Letizia Consoli, BD, Manuela Fallica, BD, Alessandra Aloisi, BD, Francesco Di Raimondo, M.D., Angelo Messina, MD, Paolo Vigneri, MD, PhD

Blood (2009) 114 (22): 2165.

https://doi.org/10.1182/blood.V114.22.2165.2165

Published: 2009

Journal Articles

Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1.

Ramesh Balusu, Warren C. Fiskus, Rekha Rao, Kathleen M. Buckley, Yongchao Wang, Atul Joshi, Sanjay Koul, Anand Jillella, Celalettin Ustun, Susan Sunay, H. Jean Khoury, Kapil N. Bhalla

Blood (2009) 114 (22): 2656.

https://doi.org/10.1182/blood.V114.22.2656.2656

Published: 2009

Journal Articles

AID splice variants lack deaminase activity

Febe van Maldegem, Ferenc A. Scheeren, R. Aarti Jibodh, Richard J. Bende, Heinz Jacobs, Carel J. M. van Noesel

Blood (2009) 113 (8): 1862–1864.

https://doi.org/10.1182/blood-2008-08-175265

Published: 2009

Journal Articles

Importin-β1 and Nucleus Transporter Chromosome Region Maintenance 1 (CRM1) Constitute the Nucleocytoplasmic Transport System of STAT3 in Blood-Derived CLL Cells.

Inbal Hazan-Halevy, PhD., David Harris, Zhiming Liu, Alessandra Ferrajoli, MD., Michael J Keating, M.D., Zeev Estrov, MD

Blood (2008) 112 (11): 1059.

https://doi.org/10.1182/blood.V112.11.1059.1059

Published: 2008

Journal Articles

Nutlin-3A, an MDM2 Antagonist, Induces p53-Dependent Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma (HL).

Elias Drakos, MD, Athanasios Thomaides, MD, Jiang Li, MD,PhD, Marina Konopleva, MD,PhD, L. Jeffrey Medeiros, MD, Michael Andreeff, MD,PhD, George Z. Rassidakis, MD,PhD

Blood (2006) 108 (11): 2506.

https://doi.org/10.1182/blood.V108.11.2506.2506

Published: 2006

Journal Articles

Targeting Mutant Nucleophosmin (NPM)1: A Promising Approach To Induce Growth Inhibition and Differentiation in Human AML.

Bryan Herger, PhD, Warren Fiskus, Ph.D., Rekha Rao, Ph.D., Kapil Bhalla, M.D.

Blood (2006) 108 (11): 1905.

https://doi.org/10.1182/blood.V108.11.1905.1905

Published: 2006

Journal Articles

The Four and a Half LIM Domain Protein 2 (FHL2) Interacts with CALM and Is Highly Expressed in AML with Complex Aberrant Karyotpes.

Zlatana Pasalic, Belay Tizazu, Leticia Archangelo, PhD, Alexandre Krause, VetMed, Greif Philipp, MD, Stefan K. Bohlander, MD

Blood (2006) 108 (11): 4337.

https://doi.org/10.1182/blood.V108.11.4337.4337

Published: 2006

Journal Articles

Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia

Blood (2006) 108 (6): 1999–2005.

https://doi.org/10.1182/blood-2006-03-007013

Published: 2006

Journal Articles

Rush hour in AML: news on NPM traffic

Konstanze Döhner, Hartmut Döhner

Blood (2006) 107 (11): 4200–4201.

https://doi.org/10.1182/blood-2006-03-008409

Published: 2006

Journal Articles

Exon-12 Nucleophosmin ( NPM ) Mutation and Aberrant Cytoplasmic Expression of NPM Protein in Leukemia Cell Line OCI-AML3.

Hilmar Quentmeier, PhD, Maria P. Martelli, PhD, Wilhelm G. Dirks, PhD, Niccolo Bolli, PhD, Arcangelo Liso, PhD, Roderick A.F. MacLeod, PhD, Ildo Nicoletti, PhD, Roberta Mannucci, PhD, Alessandra Pucciarini, PhD, Barbara Bigerna, PhD, Massimo F. Martelli, PhD, Cristina Mecucci, PhD, Hans G. Drexler, MD, PhD, Brunangelo Falini, PhD

Blood (2005) 106 (11): 2376.

https://doi.org/10.1182/blood.V106.11.2376.2376

Published: 2005

NARROW

SIX1 Is a Novel Effector Gene in CALM-AF10 Leukemia

A Role for the CRM1 Nuclear Export Receptor in HOXA Gene Deregulation and CALM-AF10 Leukemogenesis

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Development of a Pharmacodynamic Assay for XPO1 Occupancy Using Fluorescence Cross Correlation Spectroscopy (FCCS)

XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

ANKHD1 Is Required for S Phase Progression and Histone Gene Transcription in Multiple Myeloma

The CRM1 Nuclear Export Receptor Activates HOXA Gene Expression in Leukemogenesis

Cytoplasmic-Nuclear Shuttling of mTOR Protein in Multiple Myeloma Cell Lines and Primary Myeloma Cells: A New Mechanism Regulated by Pomalidomide

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells.

Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1.

AID splice variants lack deaminase activity

Importin-β1 and Nucleus Transporter Chromosome Region Maintenance 1 (CRM1) Constitute the Nucleocytoplasmic Transport System of STAT3 in Blood-Derived CLL Cells.

Nutlin-3A, an MDM2 Antagonist, Induces p53-Dependent Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma (HL).

Targeting Mutant Nucleophosmin (NPM)1: A Promising Approach To Induce Growth Inhibition and Differentiation in Human AML.

The Four and a Half LIM Domain Protein 2 (FHL2) Interacts with CALM and Is Highly Expressed in AML with Complex Aberrant Karyotpes.

Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia

Rush hour in AML: news on NPM traffic

Exon-12 Nucleophosmin ( NPM ) Mutation and Aberrant Cytoplasmic Expression of NPM Protein in Leukemia Cell Line OCI-AML3.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only